JP6431541B2 - 出血性障害の治療に対する改変セルピン - Google Patents

出血性障害の治療に対する改変セルピン Download PDF

Info

Publication number
JP6431541B2
JP6431541B2 JP2016538525A JP2016538525A JP6431541B2 JP 6431541 B2 JP6431541 B2 JP 6431541B2 JP 2016538525 A JP2016538525 A JP 2016538525A JP 2016538525 A JP2016538525 A JP 2016538525A JP 6431541 B2 JP6431541 B2 JP 6431541B2
Authority
JP
Japan
Prior art keywords
residue
serpin
thrombin
inhibition
apc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016538525A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017505114A5 (https=
JP2017505114A (ja
Inventor
ジェームズ アンドリュー ハンティントン
ジェームズ アンドリュー ハンティントン
ステファニー ポルダーデイク
ステファニー ポルダーデイク
トレヴァー バグリン
トレヴァー バグリン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cambridge Enterprise Ltd
Original Assignee
Cambridge Enterprise Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Enterprise Ltd filed Critical Cambridge Enterprise Ltd
Publication of JP2017505114A publication Critical patent/JP2017505114A/ja
Publication of JP2017505114A5 publication Critical patent/JP2017505114A5/ja
Application granted granted Critical
Publication of JP6431541B2 publication Critical patent/JP6431541B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/001—Use of materials characterised by their function or physical properties
    • A61L24/0015—Medicaments; Biocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0028—Polypeptides; Proteins; Degradation products thereof
    • A61L26/0047—Specific proteins or polypeptides not covered by groups A61L26/0033 - A61L26/0042
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8125—Alpha-1-antitrypsin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/258—Genetic materials, DNA, RNA, genes, vectors, e.g. plasmids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/418—Agents promoting blood coagulation, blood-clotting agents, embolising agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/04—Materials for stopping bleeding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Materials Engineering (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2016538525A 2013-12-13 2014-12-15 出血性障害の治療に対する改変セルピン Active JP6431541B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1322091.8A GB201322091D0 (en) 2013-12-13 2013-12-13 Modified serpins for the treatment of bleeding disorders
GB1322091.8 2013-12-13
PCT/EP2014/077783 WO2015086854A1 (en) 2013-12-13 2014-12-15 Modified serpins for the treatment of bleeding disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018204779A Division JP6723319B2 (ja) 2013-12-13 2018-10-31 出血性障害の治療に対する改変セルピン

Publications (3)

Publication Number Publication Date
JP2017505114A JP2017505114A (ja) 2017-02-16
JP2017505114A5 JP2017505114A5 (https=) 2018-06-28
JP6431541B2 true JP6431541B2 (ja) 2018-11-28

Family

ID=50030900

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016538525A Active JP6431541B2 (ja) 2013-12-13 2014-12-15 出血性障害の治療に対する改変セルピン
JP2018204779A Expired - Fee Related JP6723319B2 (ja) 2013-12-13 2018-10-31 出血性障害の治療に対する改変セルピン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018204779A Expired - Fee Related JP6723319B2 (ja) 2013-12-13 2018-10-31 出血性障害の治療に対する改変セルピン

Country Status (25)

Country Link
US (2) US9982035B2 (https=)
EP (2) EP3434689A1 (https=)
JP (2) JP6431541B2 (https=)
KR (2) KR101954945B1 (https=)
CN (2) CN105992771B (https=)
AU (2) AU2014363359B2 (https=)
CA (1) CA2933508C (https=)
CY (1) CY1121267T1 (https=)
DK (1) DK3080157T3 (https=)
EA (1) EA034050B1 (https=)
ES (1) ES2704058T3 (https=)
GB (1) GB201322091D0 (https=)
HR (1) HRP20182138T1 (https=)
HU (1) HUE042763T2 (https=)
IL (2) IL246180B (https=)
LT (1) LT3080157T (https=)
MX (1) MX357941B (https=)
NZ (1) NZ721918A (https=)
PL (1) PL3080157T3 (https=)
PT (1) PT3080157T (https=)
RS (1) RS58191B1 (https=)
SI (1) SI3080157T1 (https=)
SM (1) SMT201900016T1 (https=)
TR (1) TR201819781T4 (https=)
WO (1) WO2015086854A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010045659A1 (en) 2008-10-17 2010-04-22 American Gene Technologies International Inc. Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules
GB201322091D0 (en) 2013-12-13 2014-01-29 Cambridge Entpr Ltd Modified serpins for the treatment of bleeding disorders
JP6890831B2 (ja) 2015-07-08 2021-06-18 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド Ｈｉｖ予備免疫化および免疫療法
DK3402483T3 (da) 2016-01-15 2024-01-02 American Gene Tech Int Inc Fremgangsmåder og sammensætninger til aktivering af gamma-delta-T-celler
US10888613B2 (en) 2016-02-08 2021-01-12 American Gene Technologies International Inc. Method of producing cells resistant to HIV infection
DK3426777T3 (da) 2016-03-09 2022-04-25 American Gene Tech Int Inc Kombinationsvektorer og fremgangsmåder til behandling af cancer
US11976292B2 (en) 2016-06-08 2024-05-07 American Gene Technologies International Inc. Non-integrating viral delivery system and methods related thereto
IL284348B2 (en) 2016-07-08 2025-06-01 American Gene Tech Int Inc Hiv pre-immunization and immunotherapy
DK3585808T3 (da) * 2017-02-23 2022-01-31 Preclinics Ges Fuer Praeklinische Forschung Mbh Modificerede serpiner til behandlingen af bradykinin formidlet sygdom
CA3057142A1 (en) 2017-04-03 2018-10-11 American Gene Technologies International Inc. Compositions and methods for treating phenylketonuria
RU2663464C1 (ru) * 2018-02-26 2018-08-06 Общество с ограниченной ответственностью "Международный Биотехнологический Центр "Генериум" Комбинаторная терапия для лечения геморрагического шока
CA3117961A1 (en) * 2018-10-29 2020-05-07 Spin Therapeutics, Llc Compositions and methods for alpha-1-antitrypsin disorders
CN110051830A (zh) * 2019-03-14 2019-07-26 苏州新凝生物医药科技有限公司 一种protease nexin II\KPI蛋白突变体的应用
EP4326869A4 (en) * 2021-04-20 2025-12-10 Univ Of Louisville RECOMBINATING MICRO-NECK
WO2023118150A1 (en) 2021-12-22 2023-06-29 Royal College Of Surgeons In Ireland A conjugate for use in localising a molecule to the vascular endothelium.
EP4707391A1 (en) * 2024-09-10 2026-03-11 e-therapeutics PLC Nucleic acid compounds for zpi inhibition

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4711848A (en) 1984-03-14 1987-12-08 Zymogenetics, Inc. Site specific mutagenesis in alpha-1-antitrypsin
FR2599752B1 (fr) 1986-06-10 1989-11-03 Transgene Sa Variants de l'alpha1- antitrypsine utiles notamment comme inhibiteurs de la kallikreine
DE3705745A1 (de) 1987-02-23 1988-09-01 Behringwerke Ag Protein c-inhibitor (pci) als pharmazeutikum und in vitro-diagnostikum, verfahren zur herstellung eines solchen pharmazeutikums oder diagnostikums sowie ein mittel enthaltend pci
US5612194A (en) 1989-06-23 1997-03-18 Trustees Of The University Of Pennsylvania Methods of producing effective recombinant serine protease inhibitors and uses of these inhibitors
IE902276A1 (en) 1989-06-26 1991-01-16 Akzo Nv Serpin variants
US6566493B1 (en) 1996-11-19 2003-05-20 The University Of Vermont Peptidomimetics containing 6-peptidylamino-1-naphthalenesulfonamide moieties
WO2001055390A1 (en) 2000-01-28 2001-08-02 Human Genome Sciences, Inc. Human serpin polynucleotides, polypeptides, and antibodies
JP2002010783A (ja) 2000-06-29 2002-01-15 Jcr Pharmaceuticals Co Ltd 改変型ヒトプロテインｃインヒビター
US6924267B2 (en) 2001-09-18 2005-08-02 Suomen Punainen Risti Veripalvelu Methods and active substances for protecting organs
JP2003093063A (ja) 2001-09-20 2003-04-02 Jcr Pharmaceuticals Co Ltd 改変型ヒトプロテインｃインヒビター
EP1446150A1 (en) 2001-11-09 2004-08-18 Novo Nordisk Health Care AG Pharmaceutical composition comprising factor vii polypeptides and protein c inhibitors
FR2836143B1 (fr) 2002-02-21 2004-04-16 Servier Lab Nouveaux derives d'acides amines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CA2508276C (en) 2002-12-05 2018-03-27 Socratech L.L.C. Neuroprotective activity of activated protein c is independent of its anticoagulant activity
WO2004056309A2 (en) 2002-12-05 2004-07-08 Socratech L.L.C. Neuroprotective activity of activated protein c is independent of its anticoagulant activity
WO2006090282A2 (en) * 2005-02-28 2006-08-31 Universite De Lausanne Recombinant inhibitor proteins of an hk14 protease and use thereof
US8106002B2 (en) 2005-04-18 2012-01-31 Chugai Seiyaku Kabushiki Kaisha Anti-cancer agent comprising protein C inhibitor
CA3071172A1 (en) * 2005-12-15 2008-04-17 Gulfstream Aerospace Corporation Isentropic compression inlet for supersonic aircraft
KR101778174B1 (ko) 2006-07-05 2017-09-13 카탈리스트 바이오사이언시즈, 인코포레이티드 프로테아제 스크리닝 방법 및 이에 의해 확인된 프로테아제
WO2008059043A2 (en) 2006-11-16 2008-05-22 Crucell Holland B.V. Combination of coagulation factor viii with apc-resistant factor v
EP2081589B1 (en) 2006-11-16 2010-10-06 Crucell Holland B.V. Complementation of factor xi deficiency by factor v mutants
WO2008059009A2 (en) 2006-11-16 2008-05-22 Crucell Holland B.V. Factor v mutants for hemostasis in hemophilia
US8741844B2 (en) 2007-07-20 2014-06-03 Universite Paris-Sud Xi Use of mutated antithrombins for treating or preventing coagulation disorders
GB0714649D0 (en) 2007-07-27 2007-09-05 Univ Leuven Kath Novel viral replication inhibitors
JP2011500843A (ja) 2007-10-26 2011-01-06 オクラホマ・メディカル・リサーチ・ファウンデーション 活性化プロテインｃおよび不活性化プロテインｃに対するモノクロナール抗体
EP2055783A1 (en) * 2007-10-30 2009-05-06 VIB vzw Insect inhibiting plant serpin mutants
CN101965409A (zh) 2007-11-01 2011-02-02 罗切斯特大学 具有增加的稳定性的重组因子viii
CN110522905A (zh) * 2008-01-21 2019-12-03 德莫迪斯公司 丝氨酸蛋白酶抑制剂在治疗皮肤病中的用途
CA2749772C (en) 2009-01-16 2018-02-20 Assistance Publique-Hopitaux De Paris Mutated antithrombins, a process for preparing the same and their use as drugs
WO2010123290A2 (ko) * 2009-04-22 2010-10-28 (주)알테오젠 체내 지속성을 유지함으로 체내 반감기가 증가된 단백질 또는 펩티드 융합체, 및 이를 이용하여 체내 반감기를 증가시키는 방법
WO2011123830A2 (en) * 2010-04-02 2011-10-06 Amunix Operating Inc. Alpha 1-antitrypsin compositions and methods of making and using same
US9127274B2 (en) 2012-04-26 2015-09-08 Alnylam Pharmaceuticals, Inc. Serpinc1 iRNA compositions and methods of use thereof
EP2996713B1 (en) 2013-05-15 2019-10-02 Mor Research Applications Ltd. Compositions and methods for treating post-operative complications of cardiopulmonary surgery
GB201322091D0 (en) 2013-12-13 2014-01-29 Cambridge Entpr Ltd Modified serpins for the treatment of bleeding disorders
DK3585808T3 (da) * 2017-02-23 2022-01-31 Preclinics Ges Fuer Praeklinische Forschung Mbh Modificerede serpiner til behandlingen af bradykinin formidlet sygdom

Also Published As

Publication number Publication date
SI3080157T1 (sl) 2018-12-31
US20160311887A1 (en) 2016-10-27
EP3080157A1 (en) 2016-10-19
CN105992771A (zh) 2016-10-05
NZ721918A (en) 2019-12-20
IL262879A (en) 2018-12-31
CN110330563A (zh) 2019-10-15
HUE042763T2 (hu) 2019-07-29
TR201819781T4 (tr) 2019-01-21
PL3080157T3 (pl) 2019-03-29
CY1121267T1 (el) 2020-05-29
KR20190022945A (ko) 2019-03-06
KR101954945B1 (ko) 2019-03-07
EA201691235A1 (ru) 2016-12-30
HRP20182138T1 (hr) 2019-02-08
LT3080157T (lt) 2018-12-10
US9982035B2 (en) 2018-05-29
CA2933508C (en) 2021-04-06
IL246180A0 (en) 2016-07-31
AU2014363359A1 (en) 2016-07-21
MX357941B (es) 2018-07-31
DK3080157T3 (en) 2018-12-17
AU2018279054A1 (en) 2019-01-17
CN110330563B (zh) 2024-03-29
ES2704058T3 (es) 2019-03-14
KR102186924B1 (ko) 2020-12-04
IL246180B (en) 2018-11-29
KR20160092025A (ko) 2016-08-03
JP2019037242A (ja) 2019-03-14
WO2015086854A1 (en) 2015-06-18
PT3080157T (pt) 2019-01-11
RS58191B1 (sr) 2019-03-29
US20180273610A1 (en) 2018-09-27
EP3434689A1 (en) 2019-01-30
CA2933508A1 (en) 2015-06-18
EP3080157B1 (en) 2018-10-03
EA034050B1 (ru) 2019-12-23
JP6723319B2 (ja) 2020-07-15
MX2016007711A (es) 2016-12-09
JP2017505114A (ja) 2017-02-16
CN105992771B (zh) 2019-08-23
SMT201900016T1 (it) 2019-02-28
BR112016013591A2 (pt) 2017-10-03
US10351619B2 (en) 2019-07-16
AU2014363359B2 (en) 2019-01-03
GB201322091D0 (en) 2014-01-29

Similar Documents

Publication Publication Date Title
JP6431541B2 (ja) 出血性障害の治療に対する改変セルピン
JP7680996B2 (ja) 長時間作用型凝固因子およびその製造方法
TWI687226B (zh) 因子ｖｉｉｉ嵌合及雜交多肽，及其使用方法
JP2013502397A (ja) 出血性障害の治療および予防的治療における非静脈内投与のためのアルブミン融合凝固因子
CN119654164A (zh) 凝血因子x激活剂及其用于治疗出血性疾病的制剂
BR112016013591B1 (pt) Serpina modificada, célula recombinante que expressa a serpina, composição farmacêutica compreendendo a serpina e uso da serpina modificada para o tratamento ou prevenção de hemorragia ou para promoção de hemostasia
HK1229344B (en) Modified serpins for the treatment of bleeding disorders
HK1229344A1 (en) Modified serpins for the treatment of bleeding disorders
CN104395465A (zh) 表现出外位点介导的超级活性的FVIIa-sTF复合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171214

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180515

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20180515

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20180523

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180619

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180813

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20181009

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181102

R150 Certificate of patent or registration of utility model

Ref document number: 6431541

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250